Post

New research · Internal Medicine
Research and practice in thrombosis and haemostasis · 3h
ReviewResearch and practice in thrombosis and haemostasis · 2026

A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.

Dino Kröll, Guido Stirnimann, Dereck Wentworth
Read paper
Internal MedicineReview

Rivaroxaban prophylaxis after bariatric surgery had low bleeding rates and no thrombosis

A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.

Dino Kröll … Dereck Wentworth
Research and practice in thrombosis and haemostasis · 2026
Background

The role of direct oral anticoagulants for prevention of venous thromboembolism (venous thromboembolism) in bariatric surgery has been unclear.

Methods

Targeted literature reviews identified prospective studies of rivaroxaban ( n = 4) or apixaban ( n = 2) and retrospective studies ( n = 7) on venous thromboembolism prophylaxis in bariatric surgery.

n = 4
Results
1.9%
bleeding was rare and no clots occurred
n = 4
More results

Single-dose 10 mg rivaroxaban produced comparable systemic exposure before and after surgery, regardless of procedure type.

A noncontrolled, nonrandomized trial with risk-adapted dosing of rivaroxaban showed no thrombosis and low bleeding risk (0.9%).

More results

Single doses of 5 mg apixaban at 1, 6, and 12 months resulted in no clinically significant changes in pharmacokinetic and pharmacodynamic parameters.

A randomized controlled trial in sleeve gastrectomy patients with twice daily prophylactic apixaban or low-molecular-weight heparin resulted in no venous thromboembolism and low rates of bleeding events (2%).

“
Conclusion

Available evidence suggests that rivaroxaban and apixaban may be feasible options for thromboprophylaxis after bariatric surgery, although additional prospective studies are needed to confirm efficacy and safety.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”